{ "$schema_version": "5.4", "review_mode": "revision", "claim_restatement": { "index_wording": "Systemically administered BPC-157 accelerates tendon, ligament and gut mucosal healing in humans", "entry_form": "conjunctive causal therapeutic claim", "gradeable_restatement": "For each prespecified tissue category—tendon, ligament, and gastrointestinal mucosa—in humans with objectively confirmed injury, a defined BPC-157 product delivered systemically causes faster structural healing than concurrent control.", "restatement_required": true, "split_into": [ "SC1: systemic human exposure and target engagement", "SC2: human tendon structural healing", "SC3: human ligament structural healing", "SC4: human gastrointestinal mucosal structural healing" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "systemically administered", "determinable_before_outcome": true, "determined_from": "route and human PK evidence fixed before healing outcomes; local joint, bladder, rectal, and topical delivery are excluded", "action": "defined prospectively" }, { "qualifier": "accelerates healing", "determinable_before_outcome": true, "determined_from": "prespecified time-to-structural-repair contrast against concurrent control", "action": "defined as structural rather than symptom change" }, { "qualifier": "in humans", "determinable_before_outcome": true, "determined_from": "species and clinical eligibility at enrollment", "action": "retained" } ] }, "lay_summary": { "paragraphs": [ "The claim is that BPC-157, a synthetic 15-amino-acid peptide, makes human tendons, ligaments and the lining of the digestive tract heal faster when it is given so that it circulates through the body, rather than being placed directly into one injured spot.", "The evidence level is Γ: mechanistically plausible, with support only in partial systems. Rat experiments report better repair of tendon, ligament and stomach or bowel lining, and cell experiments suggest how the peptide might act. Most of this animal work comes from one connected research group, and a small independent rat tendon study did not find a statistically clear benefit, so confidence even in the animal picture is low. No human study has tested the claim. The published human reports are very small and uncontrolled, mostly used injections into a single site, and measured symptoms rather than tissue healing.", "The claim would be settled by controlled human trials of a well-defined product given through the body, with measured blood levels and imaging or endoscopy showing whether tissue heals faster. Until such trials exist, faster healing in people remains an untested research hypothesis. This grade describes the state of the evidence. It does not show that BPC-157 is ineffective." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C2", "C3", "C4", "C5", "C6", "C7", "C12", "C13", "C14" ], "jargon_glossed": [ "systemic: delivered so that exposure can reach tissues through the circulation", "structural healing: repair shown by imaging, endoscopy, histology, or mechanical integrity rather than symptoms alone" ], "no_practical_advice": true, "written_for": "general reader with no specialist pharmacology or repair-biology background" }, "hypothesis": { "name": "systemic BPC-157 as a human tendon, ligament, and gut-mucosal repair accelerator", "central_claim": "Systemically administered BPC-157 accelerates tendon, ligament and gut mucosal healing in humans", "proposed_mechanism": "Systemic exposure to the synthetic 15-amino-acid peptide is proposed to enhance fibroblast migration and survival, vascular responses, collagen organization, inflammation resolution, and epithelial protection, thereby increasing the rate or quality of tissue repair across several organs.", "claimed_scope": "multi-tissue structural healing in humans after systemic administration", "claimed_level": [ "therapeutic causality", "cross-tissue generalization", "human translation" ], "is_conjunctive": true, "conjunctive_note": "The statement requires a validated systemic human regimen and positive structural-healing effects in all three named tissue categories. Success in one animal model, one local route, or one symptom endpoint cannot stand in for the chain." }, "rubric_routing": { "primary_rubric": "none fits — framework ladder definitions, universal caps and the SKILL.md Step 9 boundary check govern (SKILL.md Step 5; index precedent: Psilocybin dual-phase)", "secondary_rubrics": [ "06-metabolism-aging.md (by analogy only: one-species Γ cap)", "07-psychiatry-neuromodulation.md (by analogy only: rodent / unblinded-human Γ cap)", "01-neurodegeneration.md (by analogy only: simplified-animal Γ maximum)" ], "rubrics_checked": [ "01-neurodegeneration.md", "02-cancer-biology.md", "03-epigenetics-gene-regulation.md", "04-microbiome-systemic.md", "05-immunology-inflammation.md", "06-metabolism-aging.md", "07-psychiatry-neuromodulation.md" ], "index_notes_applied": [ "No BPC-157 entry exists in hypothesis-index.md. The Psilocybin dual-phase entry's rubric-mismatch note is applied by analogy: \"The field-invariant universal hard caps and the framework's own threshold definitions carry the scoring.\"" ], "rubric_fit_note": "This is a therapeutic tissue-repair claim. Rubric 05 covers immune-mechanism hypotheses and has no tissue-repair text; rubric 06 covers aging mechanisms, and its Δ threshold concerns lifespan/healthspan. No rubric governs regenerative or therapeutic-intervention claims, and this gap is flagged for the framework. Cross-field Rule 6: every candidate rubric's analogous text sets Γ as the ceiling for a human claim supported by rodent, in vitro or unblinded human evidence, so the letter does not depend on routing.", "redteam_change": "The original routed 05 as primary ('the wound/inflammation rubric') with 06 secondary (RT-03)." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "A defined systemic BPC-157 regimen produces interpretable human exposure and target engagement suitable for testing tissue healing.", "subclaim_type": "exposure", "governing_rubric": "none fits — framework ladder + universal caps; 06/07 Γ-cap text by analogy", "claimed_scope": "human systemic exposure relevant to tissue repair", "scope": "Intravenous, subcutaneous, or intramuscular administration, plus any oral route only when human systemic exposure is measured; product identity, formulation, PK, and target engagement must be recorded before healing outcomes.", "key_evidence_anchor": "Two-person IV pilot [1] (abstract reports safety measures only; secondary PK descriptions [4,15] unverified); rat/dog ADME [11]; FDA reconstruction of rectal-route plasma non-detection; unreported registered oral PK study NCT02637284.", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "SKILL.md Step 9 boundary check: no qualifying human exposure / target-engagement evidence → Γ ceiling. Universal cap 4 is not the operative rule (no biomarker change was measured).", "rationale": "Intravenous administration to two previously exposed healthy adults has been reported; the abstract describes vital signs, routine blood chemistry and symptoms. Secondary reviews describe plasma sampling with a sub-30-minute half-life, but this could not be verified against the primary report. Rectal dosing produced no detectable plasma BPC-157; a registered oral Phase 1 PK study has no results; animal PK shows rapid, species- and route-dependent exposure. No target engagement data exist. Confidence Low: one tiny uncontrolled report and one independent animal ADME dataset." }, { "id": "SC2", "statement": "Systemically administered BPC-157 accelerates structural tendon healing in humans.", "subclaim_type": "therapeutic_causality", "governing_rubric": "none fits — framework ladder + universal caps; 06/07 Γ-cap text by analogy", "claimed_scope": "human tendon injury and repair", "scope": "Objectively confirmed tendon injury with serial MRI, ultrasound, surgical integrity, mechanical function, or validated structural repair measured against a concurrent control after a prespecified systemic regimen.", "key_evidence_anchor": "Positive rat Achilles experiments from one programme [5,6]; independent tendon-cell mechanism [7]; inconclusive independent rat repair study [13]; local, uncontrolled human knee survey [2].", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "Framework Δ definition not met at human scope (Step 9 → Γ); by analogy 06 'Mechanistic plausibility plus one-species or in vitro support caps at Γ' and 07 'Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ'.", "rationale": "Systemic rat studies from the originating programme improve several repair dimensions, and independent cell work supplies a plausible migration/survival pathway. The only independent in vivo test (n = 4 per endpoint per group) found no significant BPC-157 effect on load to failure or total histology scores. The only human musculoskeletal report used local injection and recalled pain without imaging. Confidence Low (single-programme in vivo evidence; independent test inconclusive)." }, { "id": "SC3", "statement": "Systemically administered BPC-157 accelerates structural ligament healing in humans.", "subclaim_type": "therapeutic_causality", "governing_rubric": "none fits — framework ladder + universal caps; 06/07 Γ-cap text by analogy", "claimed_scope": "human ligament injury and repair", "scope": "Objectively confirmed ligament injury with serial imaging, instrumented laxity, mechanical integrity, or validated structural repair measured against a concurrent control after a prespecified systemic regimen.", "key_evidence_anchor": "Positive rat medial-collateral-ligament experiment [8] and non-diagnostic local knee pain report [2].", "hsef_level": "Γ", "confidence": "Low", "governing_cap_or_threshold": "Framework Δ definition not met at human scope (Step 9 → Γ); 06 one-species Γ cap by analogy.", "rationale": "One rat MCL-transection study from the originating programme reports functional, biomechanical, macroscopic and histological improvement; no independent replication. No human ligament trial. Confidence Low." }, { "id": "SC4", "statement": "Systemically administered BPC-157 accelerates structural gastrointestinal mucosal healing in humans.", "subclaim_type": "therapeutic_causality", "governing_rubric": "none fits — framework ladder + universal caps; 06/07 Γ-cap text by analogy", "claimed_scope": "human gastrointestinal mucosal injury and repair", "scope": "Endoscopic or histological healing of defined gastrointestinal mucosal injury after a prespecified systemic regimen, measured against a concurrent control; bladder symptoms and locally delivered rectal treatment are outside the systemic gut claim.", "key_evidence_anchor": "Positive rat gastric/colonic studies from three groups [9,10,14]; ulcerative-colitis enema meeting abstract as reconstructed by FDA (local route, interval includes no difference).", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Framework Δ definition not met at human scope (Step 9 → Γ); the local UC trial is outside the systemic scope and null-compatible (pitfall 17).", "rationale": "Rat mucosal protection or healing is reported by the originating programme and by two independent Chinese groups (Xi'an 2004, systemic healing model; Nanjing 2020, systemic co-treatment protection model). The only controlled human study used enema delivery, exists as a meeting abstract, and its between-group interval includes no difference; FDA found no oral or SC study in UC. Confidence Moderate: the best-replicated arm, though still one species." }, { "id": "SC5", "statement": "In rat injury models, systemically administered BPC-157 improves functional, biomechanical or histological repair of tendon, ligament or gastric mucosa compared with concurrent controls.", "subclaim_type": "context_restricted_causality", "governing_rubric": "none fits — framework ladder + universal caps; 06/07 Γ-cap text by analogy", "claimed_scope": "rat experimental injury models (scope-restricted; reported, non-gating)", "scope": "Controlled in vivo rat studies with systemic (intraperitoneal, intramuscular, intragastric or drinking-water) administration after or during experimental tendon, ligament or gastric injury. Local-bath and topical arms are excluded from this subclaim.", "key_evidence_anchor": "Staresinic 2003 [5], Krivic 2006 [6], Cerovecki 2010 [8], Xue 2004 [14], Wu 2020 [10]; inconclusive independent tendon study Biçer 2026 [13].", "hsef_level": "Δ", "confidence": "Low", "governing_cap_or_threshold": "Δ crossed within the rat (cap-precedence rule). Not Ε: context boundary unmapped (Step 10). Not Ζ: one evidence class; 'different laboratories' and 'replication, however extensive' do not add a line.", "rationale": "Several controlled positive in vivo perturbations exist. Tendon and ligament efficacy rests on one connected programme, and the one independent tendon test was inconclusive; gastric results have independent support. Reported so the reader sees what the animal literature establishes; it cannot raise the human-scope letter.", "gating": false } ], "aggregation_rule": "weakest-link", "aggregation_preregistered": true, "aggregation_rationale": "The submitted statement joins systemic delivery to three distinct human structural-healing outcomes, so all gates (SC1–SC4) must hold; a rat tendon result cannot rescue a missing human gut or ligament result. SC5 scores the rat literature at its own scope under the cap-precedence rule and is reported, not gating (being higher than every gating subclaim, it cannot change the weakest link).", "primary_subclaim_id": "", "aggregation_derivation": "Gating SC1=Γ; SC2=Γ; SC3=Γ; SC4=Γ (SC5=Δ, rat scope, non-gating). Weakest-link returns Γ.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ (with SC2, tendon, as primary)", "scope_matched_would_return": "Γ (highest subclaim whose scope is human systemic healing; SC5 excluded as rat-scope)", "note": "No rule-driven swing. Only an aggregation that let the rat-scope SC5 stand in for the human claim would return Δ, and that is a scope error, not an alternative rule." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Species- and injury-model-specific repair modulation", "core_claim": "BPC-157 can modify repair in selected rodent injury models, but the magnitude, target, exposure, and tissue boundary do not yet translate into demonstrated human systemic healing.", "explains_what_nominal_does_not": "It accommodates consistent rat tendon, ligament, and gastrointestinal results together with the absence of a validated human systemic regimen or structural-healing trial.", "strongest_supporting_evidence": [ "Systemic rat Achilles repair experiments [5,6]", "Rat MCL repair experiment [8]", "Rat gastric and colonic injury experiments, including two independent groups [9,10,14]", "Rat/dog PK species difference [11]" ], "strongest_contradictory_evidence": [ "Rat tendon and ligament efficacy rests largely on one connected programme; the one independent rat tendon test was inconclusive [13]." ], "hsef_level_for_this_model": "Δ", "rationale": "Controlled in vivo perturbations establish Δ within rat systems. The context boundary has not been mapped, so Ε is not reached (SKILL.md Step 10; red-team RT-15 corrected Ε → Δ)." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Local symptom modification without demonstrated structural repair", "core_claim": "The published human signals reflect local treatment, procedure effects, pain modulation, natural history, expectation, or regression to the mean rather than proven systemic tissue regeneration.", "explains_what_nominal_does_not": "It explains why uncontrolled knee and bladder symptom reports appear positive without serial imaging, histology, systemic exposure, or concurrent controls.", "strongest_supporting_evidence": [ "Retrospective local knee pain survey [2]", "Local bladder symptom pilot [3]", "Local UC enema meeting abstract (FDA reconstruction)" ], "strongest_contradictory_evidence": [ "Positive structural and biomechanical repair in controlled rat studies [5,6,8–10,14]" ], "hsef_level_for_this_model": "Γ", "rationale": "This is the best explanation of the human reports, but those reports cannot isolate a local pharmacologic effect from bias or procedure context." }, { "rank_in_tournament": 3, "model_id": "M1", "is_nominal": true, "name": "Systemic multi-tissue human repair accelerator", "core_claim": "A defined systemic BPC-157 regimen causally accelerates tendon, ligament, and gut mucosal structural healing in humans.", "explains_what_nominal_does_not": "If true, it would unify the cross-tissue rodent literature under a clinically transferable repair effect.", "strongest_supporting_evidence": [ "Positive systemic rat tendon and ligament studies [5,6,8]", "Positive rat gastrointestinal injury studies [9,10]", "Tendon-cell migration and survival mechanism [7]", "Reported short-term IV human administration [1]" ], "strongest_contradictory_evidence": [ "No systemic human structural-healing trial", "Local-route and symptom-only human reports [1–3]", "No validated human PK/PD or target-engagement bridge [1,11]; oral PK study NCT02637284 unreported" ], "hsef_level_for_this_model": "Γ", "rationale": "The model is biologically plausible but has not crossed its first field-valid human therapeutic perturbation." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "No specific pharmacologic repair effect", "core_claim": "Apparent human benefits reflect natural history, expectation and procedure context, and the concentrated rat literature reflects laboratory-specific protocols or reporting; BPC-157 has no specific repair activity.", "explains_what_nominal_does_not": "It explains the uncontrolled human observations without assuming an active drug effect.", "strongest_supporting_evidence": [ "No controlled positive systemic human endpoint", "Null-compatible UC between-group interval (FDA reconstruction)", "Inconclusive independent rat tendon test [13]" ], "strongest_contradictory_evidence": [ "Positive controlled rat gastric results from two groups outside the originating programme [10,14]", "Independent tendon-cell mechanism work [7]" ], "hsef_level_for_this_model": "Β", "rationale": "A total-null model is too strong for the animal evidence, although it remains unresolved at the claimed human scope." } ], "tournament_summary": "Species- and injury-model-specific repair modulation ranks first: it accommodates the controlled rat results and the absent human bridge. Local symptom modification best explains the human reports. The nominal systemic multi-tissue human claim ranks third because none of its defining human structural endpoints has been tested. A total-null model fits the human data but fits poorly with independent positive rat gastric studies.", "study_separating_rank1_from_rank2": "A randomized, blinded human trial after objectively confirmed tendon repair comparing a characterized systemic BPC-157 product with placebo on serial MRI or ultrasound, mechanical function and measured exposure, with standardized rehabilitation.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Lee and Burgess 2025, IV human pilot", "source_pointer": "PMID 40131143", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Weak", "system": "two healthy human adults", "decisive_perturbation": false, "endogenous": true, "direction": "non-diagnostic", "what_it_shows": "Two infusions in two previously exposed healthy adults were reported without acute adverse findings on routine safety measures.", "what_it_does_not_show": "It does not show verified PK, target engagement, injured-tissue exposure, healing, comparative efficacy, or general safety.", "confounders_present": [ "n=2", "previous IV exposure", "healthy participants", "no comparator", "short follow-up" ], "verification": "verified", "verification_note": "PubMed abstract; PK content contested (C19, unverified).", "source_tier": "A" }, { "citation": "Lee and Padgett 2021, local knee report", "source_pointer": "PMID 34324435", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M3" ], "evidence_class": "Weak", "system": "heterogeneous human knee-pain chart review", "decisive_perturbation": false, "endogenous": true, "direction": "non-diagnostic", "what_it_shows": "Most contacted patients recalled less pain after local intra-articular injection.", "what_it_does_not_show": "It does not demonstrate systemic delivery or tendon, ligament, meniscal, or cartilage repair.", "confounders_present": [ "retrospective", "no concurrent control", "heterogeneous diagnoses", "subjective recall", "no post-treatment imaging" ], "verification": "verified", "verification_note": "Complete publisher PDF read.", "source_tier": "A" }, { "citation": "Lee, Walker, and Ayadi 2024, bladder pilot", "source_pointer": "PMID 39325560", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M3" ], "evidence_class": "Weak", "system": "human interstitial-cystitis symptom pilot", "decisive_perturbation": false, "endogenous": true, "direction": "non-diagnostic", "what_it_shows": "A local bladder-wall procedure was followed by favorable patient-reported symptoms.", "what_it_does_not_show": "The bladder is not gut mucosa, and the study did not test systemic delivery or structural healing.", "confounders_present": [ "uncontrolled", "local administration", "symptom endpoint", "small sample" ], "verification": "verified", "verification_note": "PubMed abstract plus FDA full-text synthesis read.", "source_tier": "A" }, { "citation": "Ruenzi et al. 2005 UC enema meeting abstract, as reconstructed in the FDA 2026 briefing document", "source_pointer": "FDA-MEDIA-193343 (reconstruction of Ruenzi et al. 2005 meeting abstract); context PMID 42198317", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Moderate", "system": "human ulcerative colitis", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "A randomized local-enema study produced a null-compatible between-group interval and was never located as a complete report.", "what_it_does_not_show": "It does not test a systemic route, provide a validated modern mucosal-healing endpoint, or establish efficacy.", "confounders_present": [ "meeting abstract only", "endpoint incompletely defined", "short duration", "local route", "missing follow-up" ], "verification": "verified", "verification_note": "FDA briefing queried directly (2026-09-30) for verbatim DAI results and reporting gaps; the unverifiable page pointer 'Gastroenterology 128:A584' was removed.", "source_tier": "B" }, { "citation": "Staresinic et al. 2003, rat Achilles transection", "source_pointer": "PMID 14554208; DOI 10.1016/S0736-0266(03)00110-4", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "rat Achilles transection", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Systemic treatment improved functional, biomechanical, macroscopic, and histological repair measures in this rat injury model.", "what_it_does_not_show": "It does not establish a human regimen or human structural healing.", "confounders_present": [ "single species", "surgical injury model", "translation and product comparability" ], "verification": "verified", "verification_note": "PubMed abstract read.", "source_tier": "A" }, { "citation": "Krivic et al. 2006, rat Achilles tendon-to-bone detachment", "source_pointer": "PMID 16583442; DOI 10.1002/jor.20096", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "rat Achilles tendon-to-bone detachment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Systemic treatment improved functional, biomechanical, histological, and collagen-related repair in a randomized rat experiment with protocol-blinded examiners.", "what_it_does_not_show": "It does not establish independent human replication, human PK/PD, or a clinical effect size.", "confounders_present": [ "single species", "closely connected research program", "surgical detachment model" ], "verification": "verified", "verification_note": "Complete publisher PDF read.", "source_tier": "A" }, { "citation": "Chang et al. 2011, tendon explant and fibroblast experiments", "source_pointer": "PMID 21030672; DOI 10.1152/japplphysiol.00945.2010", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "rat tendon explants and cultured fibroblasts", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "BPC-157 altered outgrowth, migration, survival under stress, spreading, and FAK-paxillin signaling in partial systems.", "what_it_does_not_show": "It does not identify a validated human molecular target or establish organismal tissue healing.", "confounders_present": [ "ex vivo and in vitro systems", "rat cells", "multiple correlated readouts" ], "verification": "verified", "verification_note": "Complete publisher HTML read.", "source_tier": "A" }, { "citation": "Cerovecki et al. 2010, rat MCL transection", "source_pointer": "PMID 20225319; DOI 10.1002/jor.21107", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Strong", "system": "rat medial collateral ligament transection", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "BPC-157 improved ligament-repair measures across systemic, oral, and local routes in rats.", "what_it_does_not_show": "It does not establish human ligament healing or systemic human exposure-response.", "confounders_present": [ "single species", "surgical model", "same broad research program as several positive studies" ], "verification": "verified", "verification_note": "PubMed abstract read.", "source_tier": "A" }, { "citation": "Duzel et al. 2017, rat ischemic colitis", "source_pointer": "PMID 29358856; PMCID PMC5752708", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "rat ischemic-colitis and reperfusion models", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Local BPC-157 treatment preserved mucosal folds and vascular presentation in a severe rat ischemia model.", "what_it_does_not_show": "The local bath does not test systemic human delivery or common inflammatory mucosal disease.", "confounders_present": [ "local route", "single species", "surgical vascular model" ], "verification": "verified", "verification_note": "Complete PMC full text read.", "source_tier": "A" }, { "citation": "Wu et al. 2020, rat recurrent gastric injury", "source_pointer": "PMID 33376304; PMCID PMC7763470", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Moderate", "system": "rat acetic-acid ulcer with clopidogrel-associated recurrence", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Intraperitoneal BPC-157 co-administered with clopidogrel after healed acetic-acid ulcers reduced ulcer recurrence, inflammation and apoptosis in rats (independent Nanjing group).", "what_it_does_not_show": "It tests protection during co-administration, not faster healing of an established lesion, and not human efficacy.", "confounders_present": [ "single species", "compound injury model", "molecular readouts are correlated with the same lesion" ], "verification": "verified", "verification_note": "Complete PMC full text read.", "source_tier": "A" }, { "citation": "He et al. 2022, rat and dog ADME", "source_pointer": "PMID 36588717; PMCID PMC9794587", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "rat and beagle-dog pharmacokinetics", "decisive_perturbation": false, "endogenous": true, "direction": "non-diagnostic", "what_it_shows": "The intact peptide is cleared rapidly and intramuscular bioavailability differs materially between species.", "what_it_does_not_show": "It does not validate any human systemic exposure, dose, tissue concentration, or target engagement.", "confounders_present": [ "nonhuman species", "prototype exposure may not equal active fragments", "healing and PK were not linked" ], "verification": "verified", "verification_note": "Complete PMC full text read.", "source_tier": "A" }, { "citation": "Vasireddi et al. 2025, systematic review", "source_pointer": "PMID 40756949; PMCID PMC12313605", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "systematic review of musculoskeletal literature", "decisive_perturbation": false, "endogenous": false, "direction": "non-diagnostic", "what_it_shows": "The human musculoskeletal evidence in the review window reduces to the local uncontrolled knee report, while the efficacy literature is preclinical.", "what_it_does_not_show": "A review cannot create a human causal line absent from its primary studies.", "confounders_present": [ "primary literature dominated by animal studies", "full body not accessible in PMC response" ], "verification": "verified", "verification_note": "PubMed abstract and partial PMC record read.", "source_tier": "B" }, { "citation": "FDA 2026 PCAC briefing document", "source_pointer": "FDA media 193343", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "regulatory evidence synthesis", "decisive_perturbation": false, "endogenous": false, "direction": "non-diagnostic", "what_it_shows": "The agency located no adequate human evidence of effectiveness in UC, no oral or SC UC study, and no human PK data after oral, SC, nasal or transdermal dosing.", "what_it_does_not_show": "It is not itself an efficacy experiment and does not prove the drug has no effect.", "confounders_present": [ "regulatory question focused on compounding and ulcerative colitis", "synthesis depends on available public reports" ], "verification": "verified", "verification_note": "FDA briefing queried directly in the red-team pass; recoded from 'contradicts/Strong' (RT-20).", "source_tier": "B" }, { "citation": "ClinicalTrials.gov NCT07437547", "source_pointer": "NCT07437547", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Administrative", "system": "planned/recruiting human systemic trial", "decisive_perturbation": false, "endogenous": true, "direction": "pending", "what_it_shows": "A controlled subcutaneous trial with MRI and return-to-sport endpoints is recruiting in muscle strain.", "what_it_does_not_show": "A registry without results is not efficacy evidence, and muscle strain is outside the exact tendon, ligament, and gut claim.", "confounders_present": [ "no posted results", "muscle rather than tendon or ligament" ], "verification": "verified", "verification_note": "Complete registry record and API JSON read.", "source_tier": "A" }, { "citation": "ClinicalTrials.gov NCT07803250", "source_pointer": "NCT07803250", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M2" ], "evidence_class": "Administrative", "system": "planned human rotator-cuff repair study", "decisive_perturbation": false, "endogenous": true, "direction": "pending", "what_it_shows": "A systemic post-rotator-cuff-repair study is registered and not yet recruiting.", "what_it_does_not_show": "The record has no results and contains design-description inconsistencies that must be resolved before interpretation.", "confounders_present": [ "no posted results", "not yet recruiting", "registry inconsistencies" ], "verification": "verified", "verification_note": "Complete registry record and API JSON read.", "source_tier": "A" }, { "citation": "Biçer et al. 2026, independent rat Achilles repair study", "source_pointer": "PMID 42542926; DOI 10.52312/jdrs.2026.2951", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Moderate", "system": "rat Achilles transection with suture repair (Sprague-Dawley)", "decisive_perturbation": true, "endogenous": true, "direction": "null (underpowered; favourable direction)", "what_it_shows": "In the only independent in vivo tendon test located, BPC-157 effects on load to failure and total histology scores were not statistically significant versus control.", "what_it_does_not_show": "With four tendons per endpoint per group it cannot show absence of effect; it neither confirms nor refutes the originating programme's results.", "confounders_present": [ "n = 4 per group", "single 4-week time point", "repaired rather than unrepaired defect", "strain differs from originating programme" ], "verification": "verified", "verification_note": "PubMed abstract plus journal full-text page.", "source_tier": "A" }, { "citation": "Xue et al. 2004, independent rat gastric-ulcer study", "source_pointer": "PMID 15052688; PMCID PMC4717094", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M2", "M1" ], "evidence_class": "Moderate", "system": "rat acute and chronic gastric-ulcer models; intramuscular and intragastric dosing", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Systemic BPC-157 reduced ulcer area and accelerated epithelial and granulation-tissue rebuilding in a chronic ulcer model, from a group outside the originating programme.", "what_it_does_not_show": "It does not establish human efficacy or a molecular target.", "confounders_present": [ "single species", "older methods reporting" ], "verification": "verified", "verification_note": "PubMed abstract.", "source_tier": "A" }, { "citation": "Independent reviews 2025-2026 (McGuire; Tewari)", "source_pointer": "PMID 40789979; PMID 42578445", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Weak", "system": "narrative / scoping reviews", "decisive_perturbation": false, "endogenous": false, "direction": "non-diagnostic", "what_it_shows": "Independent syntheses describe the human evidence as minimal and the claimed benefits as unsubstantiated or investigational.", "what_it_does_not_show": "They are not experiments and carry no new causal evidence.", "confounders_present": [ "secondary sources" ], "verification": "verified", "verification_note": "PubMed abstracts; framing artifacts for Divergence.", "source_tier": "B" }, { "citation": "Originating-programme reviews (Sikiric 2024; Matek 2026)", "source_pointer": "PMID 38980576; PMID 41754849", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "narrative reviews by the originating research programme", "decisive_perturbation": false, "endogenous": false, "direction": "non-diagnostic", "what_it_shows": "The originating programme frames efficacy as consistent across tissues and cites the UC phase II programme as clinical evidence.", "what_it_does_not_show": "They are not new experiments; they are framing artifacts.", "confounders_present": [ "authored by the programme whose studies they review" ], "verification": "verified", "verification_note": "PubMed abstracts; framing artifacts for Divergence.", "source_tier": "B" }, { "citation": "ClinicalTrials.gov NCT02637284", "source_pointer": "NCT02637284", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Administrative", "system": "registered oral Phase 1 safety/PK study in healthy volunteers", "decisive_perturbation": false, "endogenous": false, "direction": "pending (unreported)", "what_it_shows": "A randomized, placebo-controlled oral PK study was registered (start 2015-10) and has status unknown with no posted results.", "what_it_does_not_show": "No human PK data are available from it.", "confounders_present": [ "no results a decade after registration" ], "verification": "verified", "verification_note": "Registry record opened 2026-09-30; FDA also records no results.", "source_tier": "A" }, { "citation": "ClinicalTrials.gov NCT07752381", "source_pointer": "NCT07752381", "relates_to_subclaims": [], "favors_models": [], "evidence_class": "Administrative", "system": "oral product in uninjured, physically active adults", "decisive_perturbation": false, "endogenous": false, "direction": "pending (no posted results)", "what_it_shows": "A commercial oral-product study with inflammatory-marker and self-report endpoints completed in 2025-11.", "what_it_does_not_show": "No injury, no structural endpoint; cannot bear on any subclaim.", "confounders_present": [ "single arm as registered", "sponsor product" ], "verification": "verified", "verification_note": "Registry record opened 2026-09-30.", "source_tier": "A" } ], "verification_summary": { "load_bearing_claims_checked": 18, "verified": 18, "unverified": 0, "contradicted": 0, "note": "18 scored claims verified by their stated access depth. C19, explicitly not used for scoring, retired with backup because the underlying primary human PK report remains inaccessible and unverified; no inference from an abstract silence is adopted." }, "factual_issues_found": [ { "quoted_text": "Systemically administered", "problem": "The published positive human symptom reports used intra-articular, bladder-wall, or rectal delivery, so they cannot be silently relabeled as systemic evidence.", "source_says": "The IV pilot studied two healthy adults and no healing endpoint; the knee, bladder, and UC studies used local routes.", "source_pointer": "PMID 40131143; PMID 34324435; PMID 39325560; Ruenzi 2005; FDA 2026", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "accelerates ... healing", "problem": "Pain or symptom improvement is not equivalent to faster structural tissue repair.", "source_says": "The knee report used subjective telephone recall with no objective follow-up testing or post-treatment MRI; the bladder report used a symptom questionnaire.", "source_pointer": "PMID 34324435; PMID 39325560", "affects_score": true, "action": "structural endpoint required" }, { "quoted_text": "tendon, ligament and gut mucosal healing in humans", "problem": "The breadth is inferred mainly from different rodent injury models, and the bladder study concerns a different organ.", "source_says": "Human tendon, ligament, and systemic gut-mucosal structural healing have not been demonstrated in the opened literature.", "source_pointer": "PMID 40756949; FDA 2026 briefing document", "affects_score": true, "action": "subclaims separated and each capped at its tested scope" }, { "quoted_text": "It did not measure BPC-157 concentrations ... The two-person IV human pilot did not measure pharmacokinetics", "problem": "Asserted from abstract-depth access and marked verified, but the review's own source 4 states that the pilot used serial plasma sampling (half-life < 30 min), and source 15 calls it a safety/pharmacokinetics study; the primary full text could not be accessed.", "source_says": "PMID 40131143 abstract: vital signs, fasting blood work and side effects only; Mateescu 2026 (PMC13210877): 'Serial plasma sampling demonstrated a half-life of under 30 min'.", "source_pointer": "PMID 40131143; PMID 42198317; PMID 40789979", "affects_score": false, "action": "red-team: reworded; PK content registered as unverified claim C19 and not used for scoring (RT-07)" }, { "quoted_text": "searched public medical literature and trial registries through late 2025", "problem": "The FDA briefing gives no literature-search window; its FAERS/HFCS searches ran through 3–4 December 2025.", "source_says": "FDA briefing (fda.gov/media/193343).", "source_pointer": "FDA-MEDIA-193343", "affects_score": false, "action": "red-team: reworded (RT-18)" }, { "quoted_text": "Registered future studies have no results [14,15]", "problem": "Reference numbers 13–15 do not exist in a 12-item list.", "source_says": "n/a", "source_pointer": "internal", "affects_score": false, "action": "red-team: registry records cited by NCT number (RT-13)" }, { "quoted_text": "WADA temporarily placed BPC-157 on the 2022 Prohibited List ... This decision was later reversed (source 4)", "problem": "Contradicted by FDA briefing (May 2026) and USADA (modified 2026-08-10), which state BPC-157 is prohibited under S0.", "source_says": "FDA: 'BPC-157 is listed on the World Anti-Doping Agency's prohibited list under the non-approved substances (S0) section'.", "source_pointer": "PMID 42198317; FDA-MEDIA-193343; USADA", "affects_score": false, "action": "red-team: not relied on; source 4 reliability note (RT-11, RT-19)" }, { "issue": "C19 had stale load-bearing SC1 mapping despite explicit not-used-for-scoring note; unresolved human PK cannot be credited as verified.", "resolution": "Retired ancillary numeric item with exact backup; preserved unresolved human PK caveat; grades unchanged." } ], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": false, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Not triggered: no biomarker change was measured. SC1's Γ ceiling comes from the Step 9 boundary check (see boundary_check_BGD).", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric 06 by analogy (no rubric governs; RT-03)", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus one-species or in vitro support caps at Γ.", "specific_trigger": "Positive tendon evidence is from rat in vivo, rat explant, and rat-cell systems; the human report uses local delivery and symptoms without structural repair.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric 06 by analogy (no rubric governs; RT-03)", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus one-species or in vitro support caps at Γ.", "specific_trigger": "The positive ligament perturbation is a rat MCL-transection experiment with no systemic human structural counterpart.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "rubric 06 by analogy (no rubric governs; RT-03)", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus one-species or in vitro support caps at Γ.", "specific_trigger": "Positive structural mucosal evidence is in rats; the human UC trial used local enema delivery, incomplete reporting, and a null-compatible between-group interval.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric 07 by analogy", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "Tendon support is rodent in vivo, rat cells in vitro, and one uncontrolled, unblinded local human survey.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "In vitro evidence alone cannot exceed Γ.", "specific_trigger": "Applies to the tendon-cell mechanism line [7] taken alone.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Rat tendon and ligament pharmacologic perturbations cross causal thresholds within their animal injury systems, while the hypothesis claims systemic human healing.", "subclaim_scope_cap_binds_on": "SC2 and SC3 at human structural-healing scope.", "subclaim_scope_threshold_binds_on": "The specific rat Achilles and MCL injury models in sources 5, 6, and 8.", "resolution": "The animal effects are retained as causal within those systems and Γ support for translation; they are not promoted to a human Δ.", "note": "The threshold and cap bind different scopes." }, { "collision": "Rat gastrointestinal injury models show causal effects, while the human evidence concerns local enema treatment with incomplete reporting.", "subclaim_scope_cap_binds_on": "SC4 at systemic human gastrointestinal mucosal-healing scope.", "subclaim_scope_threshold_binds_on": "The rat ischemic-colitis and gastric-ulcer injury models in sources 9 and 10.", "resolution": "Positive rat effects support plausibility. The systemic human Δ threshold remains unmet.", "note": "Local rectal exposure cannot satisfy a systemic human route gate." }, { "collision": "Local human knee symptoms are favorable, but the same report lacks objective structural repair and systemic delivery.", "subclaim_scope_cap_binds_on": "SC2 and SC3 at systemic structural-healing scope.", "subclaim_scope_threshold_binds_on": "A narrow local symptom-response proposition that this review does not score as the submitted claim.", "resolution": "The symptom signal is preserved as weak human evidence and excluded from the structural-healing causal tally.", "note": "Therapeutic symptom change and repair mechanism are separate claims." }, { "collision": "Rat tendon, ligament and gastric perturbations cross Δ within their rat systems, while the claim is human and systemic.", "subclaim_scope_cap_binds_on": "SC2–SC4 (human systemic structural healing): Γ ceiling via the framework Δ definition and Step 9, with 06/07 Γ-cap text by analogy.", "subclaim_scope_threshold_binds_on": "SC5 (rat experimental injury models): Δ crossed [5,6,8,10,14].", "resolution": "Both recorded explicitly as separate subclaims (red-team RT-16). SC5 is reported and non-gating; it cannot raise the human-scope letter.", "note": "No rubric governs this claim (RT-03); the collision is resolved under the framework-level cap-precedence rule." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Framework Δ (no rubric governs): 'At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.'", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "None. The IV pilot [1] has no healing phenotype, and its PK content is unverified; rectal dosing gave no detectable plasma BPC-157; oral PK study NCT02637284 is unreported; animal ADME [11] cannot validate human exposure-response.", "gamma_hard_rules_triggered": [ "06 by analogy: 'Single-species or single-strain evidence' (exposure data are rat/dog only)" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "unclear", "perturbation_result_note": "Administration occurred, but the claimed healing system was absent.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Framework Δ (no rubric governs): 'At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.'", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "None at human scope. Rat tendon repair is positive [5,6], an independent rat test is inconclusive [13], and the local human knee survey [2] has no structural endpoint or systemic route.", "gamma_hard_rules_triggered": [ "06 by analogy: 'Single-species or single-strain evidence'", "07 by analogy: 'Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ'" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "unclear", "perturbation_result_note": "Positive in rats, untested at systemic human structural scope.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Framework Δ (no rubric governs): 'At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.'", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "Rat MCL healing is positive [8]; no systemic human ligament structural-healing experiment was found.", "gamma_hard_rules_triggered": [ "06 by analogy: 'Single-species or single-strain evidence'" ], "disease_phenotype_relevance": "no", "perturbation_result_positive": "unclear", "perturbation_result_note": "Positive in the rat model only.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Framework Δ (no rubric governs): 'At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.'", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "None at human scope. Rat gastric/colonic studies are positive [9,10,14]; the UC enema trial (meeting abstract, FDA reconstruction) is local and null-compatible; FDA found no oral/SC UC study.", "gamma_hard_rules_triggered": [ "06 by analogy: 'Single-species or single-strain evidence'", "Local route outside the systemic scope (UC enema)" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "The direct human study does not provide a positive systemic structural-healing result.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "Framework Δ (no rubric governs): 'At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.'", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Controlled in vivo rat perturbations with positive structural/functional results: Staresinic 2003 [5], Krivic 2006 [6], Cerovecki 2010 [8], Xue 2004 [14], Wu 2020 [10].", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes (within rat injury models)", "perturbation_result_positive": "yes", "perturbation_result_note": "Positive within rat systems; one independent rat tendon test inconclusive [13].", "ceiling_from_boundary_check": "Δ or higher" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Γ", "requirement_quoted": "Mechanistically plausible, partial system support", "satisfied": "yes", "supporting_evidence": [ "Human IV administration is documented [1].", "Rat/dog ADME shows measurable, route- and species-dependent systemic exposure [11]." ], "what_would_cross_it": "Already crossed at partial-system level." }, { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "First field-valid causal perturbation crossed", "satisfied": "no", "supporting_evidence": [ "No human PK/PD and healing experiment links a defined systemic regimen to tissue exposure, target engagement, and repair." ], "what_would_cross_it": "A controlled human systemic study with verified product identity, PK, tissue-relevant target engagement, and a positive structural-healing phenotype." }, { "subclaim_id": "SC2", "threshold": "Γ", "requirement_quoted": "Mechanistically plausible, partial system support", "satisfied": "yes", "supporting_evidence": [ "Systemic rat Achilles experiments improve structural and mechanical repair [5,6].", "Tendon explant and cell work supplies a coherent migration/survival mechanism [7]." ], "what_would_cross_it": "Already crossed at partial-system level." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "First field-valid causal perturbation crossed", "satisfied": "no", "supporting_evidence": [ "The local knee chart review measured recalled pain, not systemic tendon repair [2].", "The only independent rat repair test was inconclusive [13].", "NCT07803250 is not yet recruiting and has no results." ], "what_would_cross_it": "A positive randomized systemic human tendon trial with serial structural imaging or surgical integrity and measured exposure." }, { "subclaim_id": "SC3", "threshold": "Γ", "requirement_quoted": "Mechanistically plausible, partial system support", "satisfied": "yes", "supporting_evidence": [ "The rat MCL-transection experiment reports functional, biomechanical, macroscopic, and histological improvement [8]." ], "what_would_cross_it": "Already crossed at partial-system level." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "First field-valid causal perturbation crossed", "satisfied": "no", "supporting_evidence": [ "No controlled systemic human ligament-healing perturbation with structural readout was found." ], "what_would_cross_it": "A positive randomized systemic human ligament trial with serial imaging, instrumented laxity, function, and exposure measurement." }, { "subclaim_id": "SC4", "threshold": "Γ", "requirement_quoted": "Mechanistically plausible, partial system support", "satisfied": "yes", "supporting_evidence": [ "Rat colonic and gastric injury experiments report mucosal protection or healing, including two groups outside the originating programme [9,10,14]." ], "what_would_cross_it": "Already crossed at partial-system level." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "First field-valid causal perturbation crossed", "satisfied": "no", "supporting_evidence": [ "The only controlled human GI trial is a local-enema meeting abstract whose between-group interval includes no difference (FDA reconstruction).", "No systemic human endoscopic or histological healing result exists." ], "what_would_cross_it": "A positive randomized systemic human gastrointestinal trial with endoscopic and histological mucosal healing plus measured systemic exposure." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "At least one endogenous in vivo (or equivalent human interventional / natural-experiment) perturbation shows the mechanism contributes causally to the claimed phenotype.", "satisfied": "yes", "supporting_evidence": [ "Controlled positive rat perturbations [5,6,8,10,14]." ], "what_would_cross_it": "Already crossed within the rat." }, { "subclaim_id": "SC5", "threshold": "Ε", "requirement_quoted": "Context-specific causality established. The mechanism is causally operative in a defined context ... but generalization to the full claimed scope fails. (SKILL.md Step 10: 'Mapped boundary means Ε; untested means Δ.')", "satisfied": "no", "supporting_evidence": [ "No study maps where the rat effect stops (tissue, route, dose, strain, laboratory)." ], "what_would_cross_it": "Preregistered, adequately powered studies that define where the effect holds and where it stops, including independent laboratories and negative-control tissues." } ], "generalization_check": { "generalization_tested": "no", "context_boundary_mapped": "no", "internal_negative_controls": [ "Local knee pain was not accepted as tendon or ligament structural repair.", "Bladder symptoms were not accepted as gastrointestinal mucosal healing.", "Rectal enema exposure was not accepted as systemic exposure.", "Rat in vivo effects were retained at animal scope rather than promoted to humans.", "Rat and dog PK differences were treated as a translation warning.", "Registry entries without results were kept out of the efficacy tally.", "A small independent rat repair study was treated as inconclusive, not as a failed replication or a confirmation." ], "note": "The preclinical literature spans tissues and routes, but the claimed human systemic boundary has not been mapped. Product, route, injury type, background rehabilitation, and structural endpoint remain unlinked in humans." }, "falsification_patterns_met": [ { "subclaim_id": "SC2, SC5", "pattern": "Effects disappear across strains or species (rubric 06, by analogy)", "evidence": "Not tested in humans. The only cross-laboratory rat tendon test (Sprague-Dawley, repaired model, n = 4 per group) found non-significant BPC-157 effects with favourable direction [13]; this is inconclusive, not a disappearance.", "triggered": false, "downgrade_applied": false }, { "subclaim_id": "SC1–SC5", "pattern": "Benefits are explained by reduced growth, intake, or sickness (rubric 06, by analogy)", "evidence": "No evidence bears on this.", "triggered": false, "downgrade_applied": false }, { "subclaim_id": "SC4", "pattern": "A field-valid perturbation at the claimed scope returns null (pitfall 17 context)", "evidence": "The UC enema trial is null-compatible but local, so outside the systemic scope; it does not cross Δ and is not a falsification of the systemic claim.", "triggered": false, "downgrade_applied": false } ], "pitfalls_flagged": [ { "subclaim_id": "SC2-SC4", "pitfall": "7. Selective generalization", "where": "Positive rodent tendon, ligament, and gut models are not generalized directly to human systemic efficacy." }, { "subclaim_id": "SC2-SC4", "pitfall": "10. Mechanism conflation", "where": "Three tissue classes, local and systemic routes, symptoms, structure, and protection versus repair are scored separately." }, { "subclaim_id": "SC2-SC4", "pitfall": "13. Therapeutic effect treated as mechanism proof", "where": "Pain or symptom change after a local procedure is not treated as proof of tissue regeneration." }, { "subclaim_id": "SC1-SC4", "pitfall": "11. Intervention specificity assumed", "where": "A defined molecular target and validated human target engagement are absent; correlated repair pathways do not identify a rate-limiting mediator." }, { "subclaim_id": "SC2-SC4", "pitfall": "18. Causal tally inflation", "where": "Multiple rat papers from connected programs and several readouts from one experiment are not counted as independent human causal lines." }, { "subclaim_id": "SC1-SC4", "pitfall": "19. Unlinked claims", "where": "Every load-bearing route, endpoint, and numerical claim is linked to the primary record or an explicitly labeled synthesis." }, { "subclaim_id": "SC2, SC3, SC5", "pitfall": "9. Replication confused with reproduction", "where": "Repeated positive rat tendon and ligament results come from one connected programme; independent reproduction is limited to one inconclusive tendon study [13]." }, { "subclaim_id": "SC1–SC4", "pitfall": "14. Missing-control interpretation", "where": "All three human reports [1–3] lack concurrent controls." }, { "subclaim_id": "SC4", "pitfall": "17. Negative field-valid perturbation read as a crossed threshold", "where": "The existence of a placebo-controlled UC trial is not evidence of Δ; its interval includes no difference and its route was local." } ], "causal_tally_audit": { "tally_claimed_by_document": 3, "tally_after_audit": 0, "items_rejected": [ "Rat tendon perturbations are causal within rat injury systems, not systemic human tendon-healing lines.", "The rat MCL perturbation is not a human ligament-healing line.", "Rat gastric and colonic injury studies are not systemic human gut-mucosal-healing lines.", "The local knee report measures pain and lacks structural follow-up.", "The bladder pilot is neither gut nor systemic.", "The UC enema report is local, incompletely reported, and not positive at the between-group interval.", "The two-person IV study has no injury or healing endpoint.", "Registered studies without results do not enter an efficacy tally." ], "note": "Human-scope tally after audit is 0. Rat-scope (SC5) controlled positive perturbations: 5 studies [5,6,8,10,14], one evidence class; one independent rat test inconclusive [13]." }, "steelman": { "case_one_rung_higher": "A Δ case combines controlled systemic rat tendon and ligament repair [5,6,8], positive rat gastric healing and protection including two independent Chinese groups [10,14], an independent tendon-cell migration/survival mechanism [7], documented IV administration in humans without acute adverse findings [1], favourable local human symptom reports [2,3], and the existence of a placebo-controlled human UC trial. Together these could be framed as the first translational causal perturbation.", "case_one_rung_lower": "A Β case emphasizes that every human report is tiny, uncontrolled or incompletely reported, locally delivered and non-structural, that the rat tendon and ligament literature comes from one programme, and that an independent rat tendon test did not reproduce a significant effect.", "which_rejected": "Both. Δ is rejected because no human study combines systemic delivery with a positive structural-healing endpoint; the one controlled human trial was local with an interval including no difference, and evidence from different species, routes, organs and endpoints cannot be assembled into a field-valid human perturbation (Rule 5). Β is rejected because Β describes associational evidence, whereas the Γ placement rests on controlled in vivo animal perturbations (including independent positive gastric studies) and cell data, which the cap-precedence rule ceilings at Γ for the human claim rather than demoting to association.", "blocking_cap_threshold_or_missing_experiment": "The binding threshold is Δ at human scope: a randomized systemic human intervention with verified product identity, measured exposure or target engagement, a serial structural-healing endpoint, an appropriate control and tissue-specific analysis. No such trial exists." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Framework: 'Low — Small number of studies; little independent replication; ... evidence primarily from a single lab or a closely connected set of labs', and confidence 'does NOT reflect whether the reviewer believes the hypothesis is correct.' SC1–SC3 meet the Low description (tendon and ligament efficacy from one connected programme, whose authors appear on 75% of PubMed-indexed BPC-157 records; one inconclusive independent tendon test; three uncontrolled human reports from one clinician-author; no human PK). SC4 is Moderate (positive rat gastrointestinal results from the originating programme and from two independent groups). The overall band follows the gating subclaims. Red-team change from High (RT-01), which had expressed certainty in the ceiling rather than evidence density.", "rests_on_non_peer_reviewed_work": false, "rationale": "Systemic rat tendon and ligament experiments, rat gastrointestinal injury models (including two independent groups) and tendon-cell work establish biological plausibility and partial-system causal support, and cross Δ within the rat (SC5). The human literature contains a two-person IV administration report and local, uncontrolled symptom reports; the one controlled human trial was local and null-compatible. No controlled systemic structural-healing result exists in tendon, ligament or gut mucosa, so every gating subclaim is Γ." }, "role_of_mechanism": { "classification": "epiphenomenon", "plain_language": "causal role in human healing unestablished", "derivation_step_matched": "2", "scope": "claimed human scope", "derivation": "Step 1 (produced by the phenotype?): no. Step 2 ('Is there no demonstrated causal dependency in either direction, only co-occurrence?'): yes at human scope. No human study shows that healing depends on systemic BPC-157, and the human reports show treatment followed by symptom change without controls. Stop at first match → epiphenomenon.", "rat_scope_role": "reinforcing / stabilizing factor (step 5, SC5): in rat models injury precedes treatment and BPC-157 changes the subsequent repair course; not shown to initiate, be required for, or be rate-limiting for repair.", "tournament_used_as_tiebreaker": false, "note": "This label records the state of the evidence. It is not the result of an experiment showing biological inactivity. Red-team change (RT-02): the original derived 'reinforcing / stabilizing factor' from rat models (step 5). Consistent with the batch-1 psilocybin edition's treatment of human-scope roles." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Ongoing preclinical/mechanistic output (e.g., Biçer 2026 [13]; 2026 reviews and studies from the originating programme [18]). NCT07437547 is recruiting but studies hamstring muscle, outside the claimed tissues; NCT07803250 (rotator-cuff tendon) is not yet recruiting; NCT07752381 (oral product, uninjured adults) cannot bear on any subclaim.", "justification": "'Decisive work underway' requires that someone is running an experiment that could cross the next threshold. None is running for tendon, ligament or gut mucosa. Momentum becomes Decisive work underway when NCT07803250 or another systemic structural-endpoint trial in a claimed tissue begins enrolling. Red-team change (RT-05)." }, "stability": { "value": "Stable", "trigger": "None at overall level: under weakest-link the letter cannot rise without human ligament and gut-mucosal results (none registered), and a null in a 20–30-person pilot would not be a field-valid falsification. Subclaim-level trigger: a positive, internally consistent NCT07803250 result with structural imaging and measured exposure could raise SC2 to Δ.", "justification": "Framework: 'If no trigger can be named, the answer is Stable by definition.' Red-team change from Uncertain (RT-06)." }, "divergence": { "implied_level": "Contested (split: Γ / Δ / ~Η)", "implied_level_basis": "Independent syntheses and FDA [4,12,15,16] frame human benefit as unsubstantiated → Γ, gap 0. Originating-programme reviews cite 'current clinical evidence (i.e., ulcerative colitis, phase II, no side effects ...)' [17] and 'consistently demonstrated efficacy' [18] → Δ, gap +1. Clinical-use publications [1,2] and peptide-supplement marketing documented in [16] present human repair benefit as established → ~Η, gap +4.", "assessed_level": "Γ", "gap_in_rungs": "0 / +1 / +4 by framing source", "value": "Contested", "justification": "Framework: Contested applies when 'the field is genuinely split and no single implied level applies'. The original computed Η from the submitted claim's own wording rather than from field framing artifacts (RT-04). The severe gap applies to the clinical-use framing that the submitted hypothesis mirrors." }, "calibration_note": "Momentum, stability and divergence do not modify the HSEF level or confidence." }, "change_record": { "applies": true, "prior_level": "Γ", "prior_confidence": "High", "prior_source": "bpc157-systemic-human-healing-hsef-v54-scorecard.json (OpenAI Codex, HSEF v5.4, 2026-09-29)", "derived_before_consulting_prior": false, "new_level": "Γ", "new_confidence": "Low", "direction": "level held; confidence lowered", "what_moved_it": "Level held: no systemic human structural-healing perturbation exists (Δ unmet), and Β is inapplicable because controlled animal perturbations exist. Confidence lowered because the framework ties the band to independent replication and the tendon/ligament efficacy literature is concentrated in one programme, with an inconclusive independent test (RT-01). Role, routing and M/S/D re-derived (RT-02 to RT-06).", "divergence_from_other_reviewers": "This red team saw the original grade (not a blinded re-derivation). Moves to Β and Δ were tested and rejected (RT-24 to RT-27)." }, "proposed_decisive_experiments": [ { "name": "Systemic BPC-157 after rotator-cuff repair", "experiment": "Randomize adults after standardized arthroscopic rotator-cuff repair to a fully characterized systemic BPC-157 product or matched placebo on top of the same rehabilitation protocol.", "readout": "Serial MRI or quantitative ultrasound of tendon integrity and re-tear, blinded structural scoring, strength and validated function, human PK, target engagement, adverse events, and product-quality assays.", "critical_control": "Predefine lesion and repair class, surgical technique, rehabilitation, analgesia, rescue treatment, imaging time points, missing-data handling, and independent image analysis; verify comparator and enrollment fields before recruitment.", "falsifying_result": "Adequate systemic exposure and target engagement without faster structural healing, or any apparent benefit confined to pain without tissue repair.", "supporting_result": "A reproducible, clinically meaningful improvement in blinded structural healing with coherent exposure-response and functional concordance." }, { "name": "Systemic treatment of acute ligament injury", "experiment": "Randomize patients with MRI-confirmed acute grade II ligament injury to systemic BPC-157 or placebo with identical bracing and rehabilitation.", "readout": "Serial quantitative MRI or ultrasound, instrumented laxity, return-to-function, re-injury, PK/target engagement, and safety.", "critical_control": "Stratify by ligament and injury grade before randomization, centralize imaging, blind outcome assessors, and prohibit local peptide co-interventions.", "falsifying_result": "No structural or mechanical advantage despite confirmed exposure, or benefit only in subjective symptoms.", "supporting_result": "Faster structural continuity and mechanical stability replicated in an independent trial." }, { "name": "Systemic gastrointestinal mucosal-healing trial", "experiment": "In a defined gastrointestinal mucosal disease, randomize systemic BPC-157 or placebo on stable background care and separate the systemic regimen from any local luminal formulation.", "readout": "Central blinded endoscopic and histological healing, clinical remission, durability after treatment, human PK, tissue target engagement, and safety.", "critical_control": "Use a validated endpoint, adequate duration, prespecified multiplicity and missing-data rules, stable concomitant therapy, and product identity/purity testing.", "falsifying_result": "No endoscopic or histological advantage with verified systemic exposure, even if symptoms or biomarkers improve.", "supporting_result": "A replicated systemic exposure-response with concordant endoscopic, histological, and clinical improvement." }, { "name": "Independent, preregistered rat replication", "experiment": "A laboratory unconnected to the originating programme runs preregistered, adequately powered, blinded replications of the rat Achilles-transection and MCL-transection models with systemic BPC-157 versus vehicle.", "readout": "Load to failure, stiffness, functional index, blinded histology and collagen organization at prespecified time points; full outcome reporting.", "critical_control": "Preregistered sample size and analysis plan; blinded allocation and assessment; characterized peptide identity and purity; vehicle control; both repaired and unrepaired tendon models.", "falsifying_result": "Adequately powered null results across tendon and ligament models would lower SC5 and reinforce the Low confidence band.", "supporting_result": "Reproduction of structural and biomechanical benefit outside the originating programme would raise SC5 confidence (it would not raise the human-scope letter)." } ], "knowledge_gaps": [ { "name": "Human systemic PK/PD", "statement": "No verified human concentration-time data exist for a systemic route; the IV pilot's PK content is unverified, rectal dosing gave no detectable plasma levels, a registered oral PK study (NCT02637284) is unreported, and target engagement in injured tissue has never been measured.", "relevance": "Without this bridge, a null result could reflect inadequate exposure and a positive symptom result cannot be mechanistically localized." }, { "name": "Product identity and formulation", "statement": "The human reports and public uses do not establish one standardized formulation with consistent identity, purity, aggregation, and stability attributes.", "relevance": "A therapeutic causal claim must refer to a reproducible intervention rather than a peptide name shared by non-equivalent products." }, { "name": "Human structural endpoints", "statement": "Published human reports do not provide serial imaging, endoscopic, histological, or mechanical evidence of accelerated repair.", "relevance": "Symptoms and routine biomarkers cannot carry a tissue-healing claim." }, { "name": "Independent preclinical reproduction", "statement": "Rat tendon and ligament efficacy comes from one connected programme; the one independent tendon study (n = 4 per group) was inconclusive; gastric results have two independent positive studies.", "relevance": "Independent protocols and laboratories would raise confidence in the preclinical effect without by themselves proving human translation." }, { "name": "Longer-term human safety and durability", "statement": "Small, short human reports cannot characterize repeated systemic exposure, immunogenicity, product impurities, or durability of any healing effect.", "relevance": "A faster early image change is not sufficient if it is unsafe, mechanically weak, or not durable." }, { "name": "Full publication of the 2005 UC trial", "statement": "The only controlled human GI trial exists as a meeting abstract with missing methods.", "relevance": "Its design and result cannot be appraised beyond the FDA reconstruction." } ], "review_metadata": { "review_date": "2026-09-30", "reviewer": "OpenAI Codex using HSEF v5.4 (authoring, 2026-09-29); Claude (Anthropic) cross-model red-team synthesis (2026-09-30)", "evidence_base_note": "Primary human, animal, ex vivo, pharmacokinetic, registry, systematic-review, and FDA records through 2026-09-29. Full text was read wherever accessible; abstract-only and partial records are labeled. The attached HSEF v5.4 packet (SHA256 7E097D3D50D2068F68BDB1CD022DF4A045DAC46A9F25E51262EC7568E9DB11EB) was treated as methodology, not biological evidence.", "literature_tools_available": true, "literature_tools_note": "The Life Sciences Literature PubMed/PMC workflow, publisher full text, ClinicalTrials.gov records, and the FDA full briefing document were used. Scite was unavailable by user report, so citation-context counts were omitted rather than encoded as zero.", "skill_version": "5.4", "validator_run": "pass (validator 2.2, red-team edition)", "validator_warnings_addressed": "See bpc157-systemic-human-healing.validation.txt.", "redteam_evidence_note": "Red-team literature currency through 2026-09-30: PubMed searches (musculoskeletal, human, non-originating-programme GI), ClinicalTrials.gov full BPC-157 intervention search (4 records), FDA briefing and PCAC materials, anti-doping status. Scite not used (quota).", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": false, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "No sealed calibration target was supplied.", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Standalone evaluation; no sealed expected band. The red-team pass saw the original grade." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "randomized_systemic_human_perturbation", "available": false, "why_not_sufficient": "The only controlled human gut study used local enema delivery and incomplete abstract reporting; no systemic human structural-healing result exists." }, { "kind": "multiple_pharmacological_classes", "available": false, "why_not_sufficient": "No independent systemic modalities acting on a validated human BPC-157 target converge on tissue healing." }, { "kind": "dose_response_across_independent_human_populations", "available": false, "why_not_sufficient": "Human dose-response for structural healing has not been reported." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "No human healing trajectory has been shown to track systemic exposure withdrawal and rechallenge." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "The published human endpoints are short tolerability or local symptoms, not blinded structural repair." }, { "kind": "registered_future_trials", "available": true, "why_not_sufficient": "NCT07437547 (muscle, recruiting), NCT07803250 (tendon, not yet recruiting), NCT02637284 (oral PK, status unknown) and NCT07752381 (uninjured adults, completed) have no posted results; a registry plan is not a causal line." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "administrative_artifacts": [ { "external_id": "FDA-MEDIA-193343", "type": "regulatory evidence synthesis", "title": "FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), dated 2026-05-11, PCAC meeting 2026-07-23/24", "url": "https://www.fda.gov/media/193343/download", "access_depth": "full_text_complete", "opened_on": "2026-09-29", "use": "Independent reconstruction of the older UC meeting abstracts, human-route inventory, and regulatory evidence-gap check; not treated as a primary efficacy experiment.", "redteam_checked_on": "2026-09-30" }, { "external_id": "NCT07437547", "type": "trial registry", "title": "BPC 157 for Acute Hamstring Muscle Strain Repair", "url": "https://clinicaltrials.gov/study/NCT07437547", "access_depth": "full_text_complete", "opened_on": "2026-09-29", "use": "Momentum artifact; recruiting hamstring MUSCLE strain trial (outside the claimed tissues); no posted results.", "redteam_checked_on": "2026-09-30" }, { "external_id": "NCT07803250", "type": "trial registry", "title": "Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery", "url": "https://clinicaltrials.gov/study/NCT07803250", "access_depth": "full_text_complete", "opened_on": "2026-09-29", "use": "Momentum artifact only; not-yet-recruiting tendon-repair study with no posted results and internal registry inconsistencies.", "redteam_checked_on": "2026-09-30" }, { "external_id": "NCT02637284", "type": "trial registry", "title": "PCO-02 - Safety and Pharmacokinetics Trial (oral BPC-157, Phase 1)", "url": "https://clinicaltrials.gov/study/NCT02637284", "access_depth": "full_text_complete", "opened_on": "2026-09-30", "use": "SC1 evidence gap: registered human oral PK study, status unknown, no results." }, { "external_id": "NCT07752381", "type": "trial registry", "title": "Peptide gummies (containing BPC-157) on markers of inflammation, physical performance and recovery", "url": "https://clinicaltrials.gov/study/NCT07752381", "access_depth": "full_text_complete", "opened_on": "2026-09-30", "use": "Momentum context only; uninjured adults, no structural endpoint, no results." }, { "external_id": "FDA-PCAC-2026-07-23", "type": "regulatory meeting page", "title": "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee", "url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "access_depth": "full_text_complete", "opened_on": "2026-09-30", "use": "Regulatory context: agenda (BPC-157 for UC) and materials; no voting record posted at access." }, { "external_id": "NEWS-ABC-2026-07-23", "type": "news report", "title": "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list (ABC News)", "url": "https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891", "access_depth": "full_text_complete", "opened_on": "2026-09-30", "use": "Regulatory context only: 8-6 vote with 1 abstention, non-binding; not evidence." }, { "external_id": "NEWS-STAT-2026-07-23", "type": "news report", "title": "FDA advisory panel narrowly votes to allow compounding of unapproved peptides (STAT)", "url": "https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/", "access_depth": "full_text_partial", "opened_on": "2026-09-30", "use": "Regulatory context only: 'The votes are not binding'." }, { "external_id": "USADA-BPC157", "type": "anti-doping agency page", "title": "BPC-157: Experimental Peptide Creates Risk for Athletes (USADA; modified 2026-08-10)", "url": "https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/", "access_depth": "full_text_complete", "opened_on": "2026-09-30", "use": "Regulatory context only: prohibited under WADA S0." } ], "provenance_header": { "sources_total": 18, "claims_total": 18, "claims_verified": 18, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 12, "generated_by": "OpenAI Codex with HSEF v5.4 (authoring); Claude (Anthropic) red-team synthesis 2026-09-30; validator 2.2", "gate_passed": true }, "claims": [ { "id": "C1", "text": "The only published intravenous human report gave infusions on two consecutive days to two healthy adults who had both previously received intravenous BPC-157; its abstract reports vital signs, fasting blood chemistry and self-reported side effects, with no injury, comparator or healing endpoint.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "PubMed abstract and record (PMID 40131143); FDA briefing description of the study", "verified_on": "2026-09-30", "note": "Red-team rewording (RT-07): the original stated that PK was not measured; that negative is not verifiable from the abstract (see C19).", "administrative_artifact_ids": [ "FDA-MEDIA-193343" ] }, { "id": "C2", "text": "In the retrospective knee chart review, 16 of 17 patients were reached by telephone; 11 of 12 who received intra-articular BPC-157 alone reported significant pain improvement, with no specific outcome instruments, no concurrent control and no reported post-treatment imaging (the authors call for follow-up MRI).", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 34324435)", "verified_on": "2026-09-30", "note": "Dose and pre-injection imaging details from the original were removed as not re-verifiable (RT-17)." }, { "id": "C3", "text": "The interstitial-cystitis pilot treated 12 women with injections around the inflamed bladder wall during one cystoscopic procedure and assessed symptoms by Global Response Assessment; it did not study gut mucosa, systemic administration, or a structural endpoint.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 39325560); FDA briefing description", "verified_on": "2026-09-30", "note": "", "administrative_artifact_ids": [ "FDA-MEDIA-193343" ] }, { "id": "C4", "text": "The only controlled human gastrointestinal efficacy record is a 2005 meeting abstract of a locally delivered (enema) placebo-controlled trial in ulcerative colitis; in the FDA's 2026 reconstruction its between-group interval includes no difference and key design details are missing, and FDA found no oral or subcutaneous study in UC.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 4, 17 ], "verification": "verified", "verified_against": "FDA briefing document (queried directly 2026-09-30); existence of the phase II UC programme also stated in [4] and [17]", "verified_on": "2026-09-30", "note": "Numerical details appear in prose attributed to the FDA reconstruction; the primary abstract was not opened.", "administrative_artifact_ids": [ "FDA-MEDIA-193343" ] }, { "id": "C5", "text": "Intraperitoneal BPC-157 improved functional, biomechanical, microscopic and macroscopic healing measures in rat Achilles transection and tendon-to-bone detachment models from the originating programme.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 5, 6 ], "verification": "verified", "verified_against": "PubMed abstracts (PMIDs 14554208, 16583442)", "verified_on": "2026-09-30", "note": "" }, { "id": "C6", "text": "BPC-157 given intraperitoneally, in drinking water or topically was followed by consistent functional, biomechanical, macroscopic and histological improvements after rat medial collateral ligament transection.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 20225319)", "verified_on": "2026-09-30", "note": "" }, { "id": "C7", "text": "Rat gastrointestinal studies report mucosal preservation after a local bath in ischemic colitis (Zagreb), accelerated chronic gastric-ulcer healing after intramuscular or intragastric dosing (Xi'an), and reduced clopidogrel-induced ulcer recurrence with intraperitoneal co-treatment (Nanjing).", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 9, 10, 14 ], "verification": "verified", "verified_against": "PMC full text (Wu 2020); PubMed abstracts (Duzel 2017, Xue 2004)", "verified_on": "2026-09-30", "note": "" }, { "id": "C8", "text": "In rat tendon explants and cultured tendon fibroblasts, BPC-157 increased outgrowth, survival under oxidative stress, migration, spreading, F-actin formation and FAK-paxillin phosphorylation without directly increasing proliferation.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 21030672)", "verified_on": "2026-09-30", "note": "" }, { "id": "C9", "text": "In rats and beagle dogs, parent BPC-157 had an elimination half-life below 30 minutes after intravenous dosing; intramuscular bioavailability was approximately 14-19% in rats and 45-51% in dogs.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "PubMed abstract and PMC record (PMID 36588717)", "verified_on": "2026-09-30", "note": "" }, { "id": "C10", "text": "A 2025 systematic review found the musculoskeletal BPC-157 evidence base overwhelmingly preclinical, with the local uncontrolled knee report as its only clinical study.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2, 12 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 40756949)", "verified_on": "2026-09-30", "note": "" }, { "id": "C11", "text": "BPC-157 lacks a validated human systemic regimen, standardized formulation and exposure-response bridge; animal ADME shows rapid clearance and species-dependent bioavailability.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 4, 11 ], "verification": "verified", "verified_against": "PMC full text of [4]; abstract of [11]", "verified_on": "2026-09-30", "note": "" }, { "id": "C12", "text": "The evidence supports BPC-157 as a plausible repair-modifying intervention in rodent injury systems but does not establish that a defined systemic regimen accelerates structural tendon, ligament or gastrointestinal mucosal healing in humans.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4", "SC5" ], "source_ns": [ 1, 2, 5, 6, 8, 9, 10, 11, 13 ], "verification": "verified", "verified_against": "cross-study synthesis of opened records", "verified_on": "2026-09-30", "note": "" }, { "id": "C13", "text": "In an independent rat Achilles transection-and-repair study with blinded assessment and four tendons per endpoint per group, BPC-157 did not significantly change maximum load to failure (adjusted p = 0.389) or total Bonar (p = 0.273) and Movin (p = 0.601) scores versus control.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "PubMed abstract (PMID 42542926) and journal full-text page (jointdrs.org)", "verified_on": "2026-09-30", "note": "" }, { "id": "C14", "text": "The positive rat tendon and ligament efficacy studies cited here, and most of the published BPC-157 literature, originate from one connected research programme at the University of Zagreb.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 4, 5, 6, 8 ], "verification": "verified", "verified_against": "PubMed author lists of [5,6,8]; PMC full text of [4]", "verified_on": "2026-09-30", "note": "The review's own reproducible PubMed count (2026-09-30) is reported in prose as a method, not as a source claim." }, { "id": "C15", "text": "Positive rat gastric results have been reported by two groups outside the originating programme.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 10, 14 ], "verification": "verified", "verified_against": "PubMed author affiliations; PMC full text of [10]", "verified_on": "2026-09-30", "note": "" }, { "id": "C16", "text": "Independent academic syntheses from 2025-2026 describe the human evidence as minimal and the claimed musculoskeletal benefits as unsubstantiated or investigational.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 4, 12, 15, 16 ], "verification": "verified", "verified_against": "PubMed abstracts [12,15,16]; PMC full text [4]", "verified_on": "2026-09-30", "note": "Divergence framing artifact (Γ, gap 0)." }, { "id": "C17", "text": "Reviews from the originating programme present BPC-157 efficacy as consistent across tissues and cite ulcerative-colitis phase II data as clinical evidence.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 17, 18 ], "verification": "verified", "verified_against": "PubMed abstracts (PMIDs 38980576, 41754849)", "verified_on": "2026-09-30", "note": "Divergence framing artifact (Δ, gap +1)." }, { "id": "C18", "text": "Clinical-use publications present human use for tendon and knee problems as established, and commercial marketing claims accelerated recovery from musculoskeletal injury.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 1, 2, 16 ], "verification": "verified", "verified_against": "PubMed abstracts of [1,2,16]", "verified_on": "2026-09-30", "note": "Divergence framing artifact (~Η, gap +4)." } ], "citation_ledger": [ { "n": 1, "citation": "Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24.", "tier": "A", "kind": "primary", "pmid": "40131143", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40131143/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "LEE-2025-IV-PILOT", "access_depth": "abstract_metadata", "access_note": "Primary abstract and metadata checked; primary full text unavailable. Ancillary secondary-review human-PK description C19 retired from scored claim register; primary human PK remains unresolved.", "carries_claims": [ "C1", "C12", "C18" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 2, "citation": "Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.", "tier": "A", "kind": "primary", "pmid": "34324435", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34324435/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "LEE-2021-KNEE", "access_depth": "abstract_metadata", "access_note": "Red-team pass re-verified at abstract depth; the original reported a complete publisher PDF read. Details not in the abstract (dose, pre-injection MRI count) were removed as not re-verifiable.", "carries_claims": [ "C2", "C10", "C12", "C18" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 3, "citation": "Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17.", "tier": "A", "kind": "primary", "pmid": "39325560", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39325560/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "LEE-2024-BLADDER", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and publisher metadata read; the apparent PDF URL returned an HTML page. FDA's full evidence table was used for route and dose context.", "carries_claims": [ "C3" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 4, "citation": "Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625.", "tier": "B", "kind": "review", "pmid": "42198317", "doi": "10.3390/pharmaceutics18050625", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13210877/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "MATEESCU-2026-TRANSLATIONAL-REVIEW", "access_depth": "full_text_complete", "access_note": "Complete PMC full text re-read in the red-team pass. Reliability note: contains a WADA 'reversal' statement contradicted by FDA (May 2026) and USADA (Aug 2026), and describes serial PK sampling in the two-person IV pilot that the pilot's abstract does not report. Used for formulation/PK-gap framing and the concentration estimate only.", "carries_claims": [ "C4", "C11", "C14", "C16" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 5, "citation": "Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983.", "tier": "A", "kind": "primary", "pmid": "14554208", "doi": "10.1016/S0736-0266(03)00110-4", "url": "https://pubmed.ncbi.nlm.nih.gov/14554208/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "STARESINIC-2003-RAT-ACHILLES", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and bibliographic metadata read; all carried outcomes are reported in the abstract.", "carries_claims": [ "C5", "C12", "C14" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 6, "citation": "Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989.", "tier": "A", "kind": "primary", "pmid": "16583442", "doi": "10.1002/jor.20096", "url": "https://pubmed.ncbi.nlm.nih.gov/16583442/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "KRIVIC-2006-RAT-TENDON-BONE", "access_depth": "abstract_metadata", "access_note": "Red-team pass re-verified at abstract depth; randomization/blinding statements from the original's full-text read were removed as not re-verifiable here.", "carries_claims": [ "C5", "C12", "C14" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 7, "citation": "Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.", "tier": "A", "kind": "primary", "pmid": "21030672", "doi": "10.1152/japplphysiol.00945.2010", "url": "https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "CHANG-2011-TENDON-CELL", "access_depth": "abstract_metadata", "access_note": "Red-team pass verified all carried outcomes against the PubMed abstract; DOI added (was missing).", "carries_claims": [ "C8" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 8, "citation": "Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155-1161.", "tier": "A", "kind": "primary", "pmid": "20225319", "doi": "10.1002/jor.21107", "url": "https://pubmed.ncbi.nlm.nih.gov/20225319/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "CEROVECKI-2010-RAT-MCL", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and bibliographic metadata read; the publisher full text was access-restricted.", "carries_claims": [ "C6", "C12", "C14" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 9, "citation": "Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World Journal of Gastroenterology. 2017;23(48):8465-8488.", "tier": "A", "kind": "primary", "pmid": "29358856", "doi": "10.3748/wjg.v23.i48.8465", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5752708/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "DUZEL-2017-RAT-ISCHEMIC-COLITIS", "access_depth": "abstract_metadata", "access_note": "Red-team pass verified carried outcomes against the PubMed abstract; PMID added to the printed reference.", "carries_claims": [ "C7", "C12" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 10, "citation": "Wu H, Wei M, Li N, et al. Clopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157. Drug Design, Development and Therapy. 2020;14:5599-5610.", "tier": "A", "kind": "primary", "pmid": "33376304", "doi": "10.2147/DDDT.S284163", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7763470/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "WU-2020-RAT-GASTRIC-ULCER", "access_depth": "full_text_complete", "access_note": "Complete PMC full text re-read in the red-team pass: co-treatment protection design (clopidogrel ± intraperitoneal BPC-157 for 30 days after ulcers healed; n = 10 per group; blinded histology); all authors in Nanjing.", "carries_claims": [ "C7", "C12", "C15" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 11, "citation": "He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182.", "tier": "A", "kind": "primary", "pmid": "36588717", "doi": "10.3389/fphar.2022.1026182", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "HE-2022-RAT-DOG-ADME", "access_depth": "abstract_metadata", "access_note": "Red-team pass verified numbers against the PubMed abstract.", "carries_claims": [ "C9", "C11", "C12" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 12, "citation": "Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495.", "tier": "B", "kind": "review", "pmid": "40756949", "doi": "10.1177/15563316251355551", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-29", "status_checked_on": "2026-09-30", "study_id": "VASIREDDI-2025-SYSTEMATIC-REVIEW", "access_depth": "abstract_metadata", "access_note": "PMC body not returned; abstract read. Author list corrected (7 authors).", "carries_claims": [ "C10", "C16" ], "redteam_checked_on": "2026-09-30", "redteam_identifier_check": "PubMed metadata resolved; title, first author, year, journal and DOI match" }, { "n": 13, "citation": "Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822-837.", "tier": "A", "kind": "primary", "pmid": "42542926", "doi": "10.52312/jdrs.2026.2951", "url": "https://pubmed.ncbi.nlm.nih.gov/42542926/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "BICER-2026-RAT-ACHILLES-REPAIR", "access_depth": "full_text_partial", "access_note": "PubMed abstract plus targeted reading of the journal full-text page (jointdrs.org/full-text/1851/eng): n = 4 per endpoint per group; Kessler repair; blinded histopathology; coded biomechanics; adjusted p-values; no funding or conflicts declared.", "carries_claims": [ "C12", "C13" ], "added_by": "red-team 2026-09-30" }, { "n": 14, "citation": "Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World Journal of Gastroenterology. 2004;10(7):1032-1036.", "tier": "A", "kind": "primary", "pmid": "15052688", "doi": "10.3748/wjg.v10.i7.1032", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4717094/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "XUE-2004-RAT-GASTRIC-ULCER", "access_depth": "abstract_metadata", "access_note": "PubMed abstract read; Fourth Military Medical University, Xi'an (independent of the Zagreb programme).", "carries_claims": [ "C7", "C15" ], "added_by": "red-team 2026-09-30" }, { "n": 15, "citation": "McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619.", "tier": "B", "kind": "review", "pmid": "40789979", "doi": "10.1007/s12178-025-09990-7", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "MCGUIRE-2025-REVIEW", "access_depth": "abstract_metadata", "access_note": "PubMed/PMC abstract read; PMC body not returned.", "carries_claims": [ "C16" ], "added_by": "red-team 2026-09-30" }, { "n": 16, "citation": "Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. American Journal of Sports Medicine. 2026 (online 2026-08-11).", "tier": "B", "kind": "review", "pmid": "42578445", "doi": "10.1177/03635465261464420", "url": "https://pubmed.ncbi.nlm.nih.gov/42578445/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "TEWARI-2026-SCOPING-REVIEW", "access_depth": "abstract_metadata", "access_note": "PubMed abstract read.", "carries_claims": [ "C16", "C18" ], "added_by": "red-team 2026-09-30" }, { "n": 17, "citation": "Sikiric P, Sever M, Krezic I, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024;32(5):3119-3161.", "tier": "B", "kind": "review", "pmid": "38980576", "doi": "10.1007/s10787-024-01499-8", "url": "https://pubmed.ncbi.nlm.nih.gov/38980576/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "SIKIRIC-2024-REVIEW", "access_depth": "abstract_metadata", "access_note": "PubMed abstract read; used only as a framing artifact for Divergence.", "carries_claims": [ "C4", "C17" ], "added_by": "red-team 2026-09-30" }, { "n": 18, "citation": "Matek D, Matek I, Japjec M, et al. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157—A Review. Pharmaceuticals (Basel). 2026;19(2):309.", "tier": "B", "kind": "review", "pmid": "41754849", "doi": "10.3390/ph19020309", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12944561/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-09-30", "status_checked_on": "2026-09-30", "study_id": "MATEK-2026-REVIEW", "access_depth": "abstract_metadata", "access_note": "PubMed abstract read; used only as a framing artifact for Divergence.", "carries_claims": [ "C17" ], "added_by": "red-team 2026-09-30" } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": false, "note": "No subclaim is Ζ or above. Independence audit recorded anyway: rat tendon/ligament efficacy [5,6,8] and colonic study [9] come from one programme (shared protocol/reporting failure mode); independent groups: Xue 2004 [14] and Wu 2020 [10] (gastric, positive), He 2022 [11] (ADME), Chang 2011 [7] (in vitro), Biçer 2026 [13] (tendon, inconclusive). All three human reports [1–3] share one clinician-author and journal." }, "edition": "HSEF v5.4 review — Red-Team Synthesis Edition (2026-09-30)", "falsification_note": "Red-team correction (RT-12): the original recorded four limitations as falsification patterns with downgrade_applied=true while applying no downgrade. Those limitations (symptom endpoints, local route, missing PK, untested cross-species generalization) are carried in the boundary check and pitfalls. No rubric falsification pattern is triggered.", "redteam_synthesis": { "date": "2026-09-30", "red_team_model": "Claude (Anthropic), cross-model red team; authoring model(s) differed", "inputs": [ "bpc157-systemic-human-healing-hsef-v54-review.md", "bpc157-systemic-human-healing-hsef-v54-scorecard.json", "bpc157-systemic-human-healing-hsef-v54-validation.txt", "README-bpc157-systemic-human-healing-hsef-v54.txt" ], "mode": "single-version red team", "findings_total": 27, "findings_accepted": 23, "findings_rejected": 4, "findings_by_severity_accepted": { "Critical": 0, "Major": 10, "Minor": 12, "Editorial": 1 }, "score_before": { "level": "Γ", "confidence": "High", "role": "reinforcing / stabilizing factor", "momentum": "Decisive work underway", "stability": "Uncertain", "divergence": "Severe overstatement" }, "score_after": { "level": "Γ", "confidence": "Low", "role": "epiphenomenon (causal role in human healing unestablished; rat scope: reinforcing / stabilizing factor)", "momentum": "Mechanistic only", "stability": "Stable", "divergence": "Contested" }, "grade_changed": false, "grade_change_rationale": "Letter held at Γ: no systemic human structural-healing perturbation exists (Δ unmet at human scope), and Β does not apply because controlled in vivo animal perturbations exist (Γ = partial-system causal support under the cap-precedence rule). Confidence lowered High → Low because the framework ties the band to independent replication and the rat tendon/ligament efficacy evidence is concentrated in one programme with an inconclusive independent test; role re-derived at human scope (step 2); routing, Momentum, Stability and Divergence corrected.", "citations_checked": 18, "citations_corrected": 2, "citations_removed": 0, "citations_added": 6, "administrative_records_checked": 9, "audit_trail": "redteam/REDTEAM_REPORT.md; redteam/SYNTHESIS_CHANGE_LOG.md" }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Framework: 'Low — Small number of studies; little independent replication; ... evidence primarily from a single lab or a closely connected set of labs', and confidence 'does NOT reflect whether the reviewer believes the hypothesis is correct.' SC1–SC3 meet the Low description (tendon and ligament efficacy from one connected programme, whose authors appear on 75% of PubMed-indexed BPC-157 records; one inconclusive independent tendon test; three uncontrolled human reports from one clinician-author; no human PK). SC4 is Moderate (positive rat gastrointestinal results from the originating programme and from two independent groups). The overall band follows the gating subclaims. Red-team change from High (RT-01), which had expressed certainty in the ceiling rather than evidence density.", "rests_on_non_peer_reviewed_work": false, "rationale": "Systemic rat tendon and ligament experiments, rat gastrointestinal injury models (including two independent groups) and tendon-cell work establish biological plausibility and partial-system causal support, and cross Δ within the rat (SC5). The human literature contains a two-person IV administration report and local, uncontrolled symptom reports; the one controlled human trial was local and null-compatible. No controlled systemic structural-healing result exists in tendon, ligament or gut mucosa, so every gating subclaim is Γ." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Low", "confidence_rationale": "Framework: 'Low — Small number of studies; little independent replication; ... evidence primarily from a single lab or a closely connected set of labs', and confidence 'does NOT reflect whether the reviewer believes the hypothesis is correct.' SC1–SC3 meet the Low description (tendon and ligament efficacy from one connected programme, whose authors appear on 75% of PubMed-indexed BPC-157 records; one inconclusive independent tendon test; three uncontrolled human reports from one clinician-author; no human PK). SC4 is Moderate (positive rat gastrointestinal results from the originating programme and from two independent groups). The overall band follows the gating subclaims. Red-team change from High (RT-01), which had expressed certainty in the ceiling rather than evidence density.", "rests_on_non_peer_reviewed_work": false, "rationale": "Systemic rat tendon and ligament experiments, rat gastrointestinal injury models (including two independent groups) and tendon-cell work establish biological plausibility and partial-system causal support, and cross Δ within the rat (SC5). The human literature contains a two-person IV administration report and local, uncontrolled symptom reports; the one controlled human trial was local and null-compatible. No controlled systemic structural-healing result exists in tendon, ligament or gut mucosa, so every gating subclaim is Γ." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\bpc-157-tissue-repair\\consensus-browser-links.json", "sha256": "b8f73ac516d69cbd34b135c76c2038785c30483260843fa066aee1e47311ddc7" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\bpc-157-tissue-repair\\consensus-browser.txt", "sha256": "6bc9a8add7dab81ec8c265f4bc557824984cc155af2ce4fc195e3c3842a4067c" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\bpc-157-tissue-repair\\consensus-pro-links.json", "sha256": "6a7285d9abb7a9a9ca0fb5a68e824cba0c36548db2aca7cf3453729d5d3186a1" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\bpc-157-tissue-repair\\consensus-pro.txt", "sha256": "328aa88339c89a7e82db7a1b5abccb9e78bf463840bbafe0e0d46f1fdc06cc16" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\bpc-157-tissue-repair\\consensus-targeted-check.txt", "sha256": "3cd3f29621cb9a5c6666f807c9bdef48681b277b6258603cd78510ce1723eab1" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "bpc-157-tissue-repair", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/bpc-157-tissue-repair/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/bpc-157-tissue-repair/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/bpc-157-tissue-repair/consensus-browser-links.json" ], "reconciliation_existing": "Yes; dated update lists 11 primary identifiers and Results/Methods check on rat/dog pharmacokinetics and material identity; human exposure not measured.", "primary_sources_matched": [ "14554208", "15052688", "16583442", "20225319", "21030672", "29358856", "34324435", "36588717", "39325560", "40131143", "42542926" ], "limitations": "No inference from provider full-text claim to human efficacy; selected source-level checks only. No conversation thread IDs in link file." } } }